StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Free Report) in a research note published on Monday. The brokerage issued a sell rating on the stock.
Ampio Pharmaceuticals Price Performance
NYSE:AMPE opened at $0.14 on Monday. The company has a market cap of $159,600.00, a P/E ratio of -0.01 and a beta of 2.15. Ampio Pharmaceuticals has a twelve month low of $0.09 and a twelve month high of $8.30. The business has a 50 day moving average price of $0.23 and a two-hundred day moving average price of $1.13.
Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($2.48) EPS for the quarter.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Featured Articles
- Five stocks we like better than Ampio Pharmaceuticals
- What is a SEC Filing?
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Progress Software Stock Back in the Green After Beating Forecasts
- How Can Investors Benefit From After-Hours Trading
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
